KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) EPS (Weighted Average and Diluted) (2019 - 2025)

Moderna (MRNA) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$2.11 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 27.49% to -$2.11 in Q4 2025 year-over-year; TTM through Dec 2025 was -$7.26, a 21.77% increase, with the full-year FY2025 number at -$7.26, up 21.77% from a year prior.
  • EPS (Weighted Average and Diluted) was -$2.11 for Q4 2025 at Moderna, down from -$0.5 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $11.29 in Q4 2021 to a low of -$9.46 in Q3 2023.
  • A 5-year average of $0.98 and a median of $0.11 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 2183.87% in 2021, then crashed 1766.67% in 2025.
  • Moderna's EPS (Weighted Average and Diluted) stood at $11.29 in 2021, then crashed by 67.58% to $3.66 in 2022, then plummeted by 84.7% to $0.56 in 2023, then tumbled by 619.64% to -$2.91 in 2024, then rose by 27.49% to -$2.11 in 2025.
  • Per Business Quant, the three most recent readings for MRNA's EPS (Weighted Average and Diluted) are -$2.11 (Q4 2025), -$0.5 (Q3 2025), and -$2.13 (Q2 2025).